Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. Our lead product candidate, THB001, is the first highly selective, oral small-molecule KIT inhibitor to enter clinical development. With promising drug-like properties and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Investors 2
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| 21.02.2022 | Atlas Vent... | atlasventu... |
Mentions in press and media 6
| Date | Title | Description |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 25.07.2023 | Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 | - |
| 25.07.2023 | Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 | - |
| 23.08.2022 | Third Harmonic Files for $150M IPO | - |
| 17.02.2022 | Third Harmonic Bio Snares $105M in Series B | CAMBRIDGE, MA, Third Harmonic Bio, a clinical-stage allergy solutions company, has closed a $105M Series B funding. >> Click here for more funding data on Third Harmonic Bio >> To export Third Harmonic Bio funding data to PD... |